LGND

Ligand is a capital-light biopharma royalty and partnering company: it earns royalties on partners' drug sales (Kyprolis, Filspari, Capvaxive, Ohtuvayre, Vaxneuvance and others), sells its Captisol formulation technology, and books contract/milestone income. The underlying royalty engine is genuinely growing — total royalties rose 48% to $161M in FY2025 (Filspari +162% to $32.0M, Capvaxive to $10.1M, Ohtuvayre to $9.8M), and total revenue grew 60.4% to $268M. The model is asset-light with low leverage (0.53x) and a clean balance sheet ($175M cash, $832M current assets).

The critical caveat is earnings quality. FY2025 net income of $124M (EPS $6.13) was dominated by non-operating items, not operations: the MD&A shows $118.0M of total non-operating income, including a $90.7M fair-value gain on Pelthos securities and $53.1M of one-time income from the LNHC divestiture. Operating income was only $41M (a 15.3% operating margin), so the reported 46.4% net margin and the 2,886% EPS jump are flattered by mark-to-market and transaction gains that may reverse or not recur. R&D also jumped 279% to $81.2M on royalty-funding arrangements.